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ABSTRACT 
The effects of 6 months of replacement therapy with recombinant 
human GH fhGH) on physical work capacity and cardiac structure 
and function were investigated in 20 patients with hGH deficiency of 
adult onset in a double blind, placebo-controlled trial. The GH dose 
of 12.5 pg/kg BW was self-administered daily SC. Oxygen consumption 
(VO,), CO, production, and ventilatory volumes were measured dur- 
ing exercise on a bicycle spiroergometer. M-Mode echocardiography 
was performed using standard techniques. The VO, max data, ex- 
pressed per kg BW fmL/min.kg BW) showed a significant increase 
from 23.2 t 2.4 to 30.0 + 2.3 U’ < 0.01) in the hGH-treated group, 
whereas the VO, max data, expressed per lean body mass (milliliters 
per mm/kg lean body mass) did not change significantly in either 
mOUD. Maximal O., nulse (milliliters ner beat) increased significantly 
from’ 15.2 & 5.6 tb’ 19.6 t 3.3 mL/beat P < O.Ol), but-remained 
constant in the placebo group. The maximal power output (watts + 
SE) increased significantly (P < 0.01) from 192.5 -C 13.5 to 227.5 -C 11.5 
in the hGH-treated group, but remained constant in the placebo 
group. Cardiac structure (left ventricular posterior wall, interven- 
tricular septum thickness, left ventricular mass, left ventricular end- 
systolic dimension, and left ventricular end-diastolic dimension) as 
well as echocardiographically assessed cardiac function did not 
change significantly after 6 months of treatment in either group. We 
conclude that hGH replacement in hGH-deficient adults improves 
oxygen uptake and exercise capacity. These improvements in pulmo- 
nary parameters might be due to an increase in respiratory muscle 
strength and partly to the changes in muscle volume per se observed 
during hGH replacement therapy. Furthermore, an increased cardiac 
output might contribute to the improvement in exercise performance 
during hGH treatment. 
According to our data, hGH replacement therapy leads to an im- 
provement of exercise capacity and maxima1 oxygen uptake, but has 
no significant effect on cardiac structure. (J Clin Endocrinol Metab 
80: 552-557, 1995) 
G H IS SECRETED from the anterior lobe of the pituitary gland throughout life, although the amounts released 
gradually decline with increasing age (1, 2). The physiolog- 
ical importance of sustained GH secretion in adulthood is 
still poorly understood. In children with GH deficiency, 
treatment with GH, besides promotion of longitudinal bone 
growth, has important effects on body composition (3,4). In 
adults, GH deficiency is associated with a reduction in lean 
body mass and an increase in body fat mass (5). Furthermore, 
adults with panhypopituitarism often do not feel well de- 
spite adequate hormone replacement therapy with thyroid 
hormone and adrenal and sex steroids, but not GH. In a 
recent study, Bengtsson and co-workers (6) showed that hu- 
man GH (hGH) replacement therapy in hGH-deficient adults 
results in marked alterations in body composition, especially 
a considerable loss of body fat and an increase in muscle 
volume. Whether these changes observed during hGH ther- 
apy will cause functional improvements and, therefore, will 
justify the cost (7) of the replacement therapy is a matter of 
controversial discussion. We performed a double blind, pla- 
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cebo-controlled trial of hGH replacement therapy in 20 pa- 
tients suffering from GH deficiency acquired in adulthood. 
The aim of our study was to evaluate whether the alterations 
in body composition observed during hGH replacement 
therapy lead to improved exercise capacity and power out- 
put and, therefore, are beneficial for our patients in perform- 
ing their daily tasks. We report the effects of hGH treatment 
on pulmonary parameters and physical work capacity in 
adults with GH deficiency after a 6-month treatment period. 
A recent study (8) suggests that GH replacement therapy 
in GH-deficient adults might affect cardiac function and 
structure. As cardiac function is an important determinant of 
exercise performance, we additionally investigated the ef- 
fects of hGH on these cardiac parameters in our patients. 
Methods 
Twenty patients, ranging in age from 27-60 yr (15 males and 5 
females), with a mean body mass index of 30.2 kg/m’ participated in the 
study. All patients had acquired GH deficiency during adulthood, gen- 
erally as a consequence of treatment for pituitary tumors, and received 
stable hormone replacement with corticosteroid, T,, and gonadal ste- 
roids for at least 12 months before entry into the trial (Table 1). With the 
exception of 1 male subject in the hGH-treated group, who did not 
require gonadal steroid replacement therapy, all of our patients received 
adequate and constant gonadal steroid-replacement therapy for 12 
months before and during the trial. To minimize the influence of dif- 
ferent gonadal steroid levels, all of the female patients were studied 
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TABLE 1. Clinical details of subjects 
Placebo group Verum group 
(n = 10) (n = IO) 
Mean age (yr) 
Range (yr) 
Sex (M/F) 
Known duration of GH 
deficiency (yr) 
Chromophobe adenoma 
Prolactinoma 
Craniopharyngioma 
Others” 
Ht (cm) 
Wt (kg) 
BMI (kg/m’) 
45.1 44.2 
27-60 28-60 
614 9/l 
8 6 
2 4 
1 1 
2 2 
5 3 
170.2 e 3.3 172.6 2 2.6 
86.3 2 5.4 90.8 + 3.6 
29.9 2 0.5 30.4 2 0.5 
Basal IGF-I (ng/mL) 55.8 -c 10.4 62.4 2 11.6 
Data are presented as the mean 2 SE. 
0 Others include one Sheehan syndrome, one empty sella syn- 
drome, one Histiocytosis X and traumatic brain injuries. 
during the first half of an artificial menstrual cycle. Male patients were 
studied in the second week of a 3-week dose interval. 
Smoking habits (only three of the patients in the verum group were 
occasional smokers of fewer than five cigarettes per day; none of the 
placebo group was a smoker) were unchanged during the trial and 
played a minor role in our patients. The nature of the trial was explained 
to the patients, and their written informed consents were obtained. The 
study protocol was approved by the local ethics committee. Entry cri- 
teria included insulin-like growth factor (IGF-I) levels [measured by the 
method of Blum et al. (9)J below 120 ng/mL and a hGH stimulation test 
(insulin tolerance test or arginine infusion (30 g) in the case of contra- 
indications to insulin tolerance test), with a peak GH response below 2 
ng/mL. Biosynthetic hGH was given in the double blind, placebo- 
controlled trial over a treatment period of 6 months. GH was self- 
administered SC daily before bedtime in a dose of 12.5 pg/kg BW. Study 
material, labeled identically for hGH- and placebo-containing vials, was 
provided by Eli Lilly Co. (Erl Wood, United Kingdom). Randomization 
of the 20 patients to study numbers was performed by Eli Lilly Co. 
Exercise tests were performed at baseline and after 6 months of treat- 
ment. The tests were performed in the morning, and standard replace- 
ment therapy was taken in the morning of the visit before the tests 
started. Venous blood samples were taken after an overnight fast. 
After all patients had completed the 6-month, double blind, placebo- 
controlled period, IGF-I levels were analyzed, and those 10 patients 
showing a marked increase in IGF-I levels during treatment were con- 
cluded to have received GH (verum), whereas those showing no alter- 
ation in IGF-I levels were concluded to have received placebo. The 
replacement trial is being continued in a single blinded manner, i.e. the 
patients are still blinded. 
Exercise test 
Height and weight was measured on the day of the visit. Patients 
were positioned on a cycle ergometer in a semirecumbent position and 
requested to pedal with a frequency of 40-50 rpm. Clips were fitted, and 
the seat height was adjusted. Before starting the measurements, the 
patients had a resting period for steady state ventilation. 0, consump- 
tion (VO,), CO, production (VCO,) from a mixing chamber, and ven- 
tilatory volumes as well as heart frequency and blood pressure were 
measured with an Ergotest machine (Fa. JBger, Wiirzburg, Hochberg, 
Germany). This machine uses infrared CO, and paramagnetic 0, ana- 
lyzers and a turbine pneumotachygraph, recording every 15 s. Calibra- 
tion against standard gases (16% 0, and 4% CO,), volume (1000 mL), 
operating temperature, and barometric pressure was performed imme- 
diately before each test. Data analyses were performed with the J-Lab- 
system, using a RSX-DEC System (Fa. Jager). The work rate was set at 
50 watts for the first minute and was increased by 25 watts every minute 
until an exhaustion-limited maximum was reached. Heart rate was 
recorded by surface electrocardiography during the entire exercise pe- 
riod. Blood pressure was measured in 1-min intervals. 0, pulse was 
defined as VO, max divided by heart rate and reflects an approximation 
of stroke volume, under the assumption that arterio-venous 0, content 
differs little between individuals at maximal exercise. 
The ventilatory anaerobic threshold was calculated from a diagram 
of VO, vs. VCO, and minute ventilation. Manual curve fitting was 
performed by one observer blinded to the origin of the graph being 
assessed. 
Measurements of lean body mass were performed with a total body 
potassium-40 y-counter. The measurements of total body potassium 
were compared with predicted normal values according to sex, age, 
height, and weight (10). Lean body mass was calculated on the assump- 
tion that there is 60 mmol potassium/kg lean body mass in women and 
66 mmol/kg lean body mass in men (11). 
Echocardiography 
Transthoracic echocardiograms were obtained with subjects in the left 
lateral decubitus position. All echocardiograms were performed by the 
same investigator, blinded to the treatment code, using a commercially 
available electronic sector scanner (SSH 40, Toshiba Medical Systems 
Europe, Delft, The Netherlands) with a 2.5.megahertz phased array 
transducer. Two-dimensional guided M-mode recordings were ob- 
tained from the parasternal window. From the M-mode recording, the 
following measurements were made using American Society of Echo- 
cardiography standards (12): interventricular septal thickness, posterior 
wall thickness, left ventricular end-diastolic dimension (LVEDD), and 
left ventricular end-systolic dimension (LVESD). Left ventricular mass 
(LVM) was calculated from the M-mode measurements using the for- 
mula modified by Devereux et al. (13) and was indexed to body surface 
area. The echocardiographic examination and the exercise test were 
performed on the same day. 
Statistics 
Results were expressed as the mean ? SE. Statistical analysis within 
each of the two treatment groups was performed with a paired Wilcoxon 
test; P < 0.05 was considered significant. Differences in the mean values 
between both groups at baseline were compared by Mann-Whitney U 
test; P < 0.05 was again considered significant. The interassay coeffi- 
cients of variation for the response variables for IGF-I measurement, 
ventilation parameters, cardiac parameters, and lean body mass mea- 
surement were all below 10%. 
Results 
Effects of treatment with hGH 
Fasting serum concentrations of IGF-I and lean body mass. IGF-I 
levels (USE), as measured by the method of Blum et al. (9), 
increased from 62.4 + 11.6 to 303.1 + 48.9 ng/mL (P < 0.005) 
in 10 of our patients, but remained constant in 10 others (from 
55.8 ? 10.4 to 58.8 + 9.5 ng/mL). Lean body mass (*SE) 
increased in the verum group from 52 + 1.9 to 56.6 + 2 kg 
(P < 0.011, but remained constant in the placebo group (from 
47 k 3.9 to 49.9 ? 3.1 kg). 
Maximal oxygen consumption (VO, max), maximal O2 pulse, 
exercise time, anaerobic threshold, and maximal power output. The 
VO, max (2s~) increased significantly from 1.9 t 0.2 to 
2.6 2 0.18 L/min (P < 0.01) in the group treated with hGH, 
whereas in the placebo group, no significant changes (from 
1.9 ? 0.18 to 2.2 ? 0.18 L/min) could be detected. 
The data, expressed per kg BW (2s~) showed a significant 
increase in VO, max from 23.2 ? 2.4 to 30 + 2.3 L/min.kg 
BW (P < 0.005) after a 6-month GH treatment period in the 
verum group, but there was no significant increase in the 
placebo group (from 22.2 2 1.9 to 25.6 +- 2.0). When ex- 
pressed as a percentage of the expected value, the VO, max 
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per kg BW increased significantly in the verum group from 
81.8 -C 10.2% to 110.8 t 7.9% (P < 0.005), but showed no 
significant increase in the placebo group (from 84.6 ? 5.9% 
to 98.1 ? 8.1%; Fig. 1). 
Maximal 0, pulse (&SE) increased significantly from 
15.2 & 5.6 to 19.6 ? 3.3 ml/beat (P < 0.01 in the hGH-treated 
group), but remained constant in the placebo group (14.3 ? 1.2 
to 16.3 + 1.1 ml/beat; Fig. 1). 
The VO, max data, expressed per kg lean body mass did 
not change significantly in either group (hGH, from 39.8 ? 
9.4 to 44.1 ? 6.6 mL/min.kg; placebo, from 41.4 + 16.8 to 
44.8 2 11.2 mL/min.kg). 
The maximal power output (&SE) achievable by the pa- 
tients increased significantly from 192.5 ? 13.5 to 227.5 -+ 11.5 
watts (P < 0.01) after 6 months in the verum group, but 
hGH *** 
Placebo 
2 4 6 
Months 
0 2 4 6 
Months 
FIG. 1. Changes in maximal 0, uptake, expressed as a percentage of 
the expected value (top) and changes in maximal 0, pulse (bottom) 
after GH treatment (closed symbols) or placebo (opera symbols). Values 
are the mean 2 SE. No significant differences existed between groups 
at baseline: **, P < 0.01; *‘$*, P < 0.005. 
showed no significant changes (from 187.5 5 16.8 to 192.5 t 
14.9 watts) in the placebo group (Fig. 2). 
The same result was found when the power output data 
were expressed per kg BW [hGH, 2.2 + 0.17 and 2.4 ? 0.18 
(P < 0.01); placebo, 2.1 2 0.19 and 2.1 ? 0.13 at 0 and 6 
months, respectively]. When the data were expressed as 
watts per kg lean body mass, no significant change could be 
detected in either group (hGH, 3.7 +- 0.3 and 3.5 + 0.3; 
placebo, 3.8 + 0.2 and 3.8 + 0.1 at 0 and 6 months, respec- 
tively; Table 2). 
The exercise time (?SE) sustained and, thereby, the total 
work performed by the patients under the protocol specified 
in Materials and Methods increased significantly in the verum 
group from 6.35 + 0.6 to 6.77 + 0.5 watts (P < 0.05), whereas 
there were no significant changes in the placebo group (from 
6.05 k 0.7 to 6.17 ? 0.6). 
The product of power output and operating time (watts X 
min 5s~) showed a significant increase in the verum group 
from 1274.4 ? 201 to 1439.1 z? 198 (P < 0.05) after 6 months 
of treatment, whereas in the placebo group, no significant 
change (from 1182 ? 204.9 to 1212.6 t 197) was found. 
The maximal ventilation (2s~) increased significantly in 
the verum group from 53.4 + 6.3 to 59.4 ? 6.0 L/min (P < 
0.05), whereas in the placebo group, no significant changes 
could be observed (from 50.5 ? 5.3 to 53.9 ? 5.7 L/min; 
Table 2). 
Changes in the anaerobic threshold, expressed per kg BW, 
showed the same results. The anaerobic threshold (&SE) in- 
creased in the hGH group significantly from 16.88 + 1.8 to 
20.44 2 1.7 mL/min.kg (P < 0.01) as well as in the placebo 
group, where we found a smaller, but significant, increase 
from 16.04 -C 1.0 to 18.42 ? 1.2 mL/min.kg (P < 0.05). 
Cardiac parameters nnd blood pressure 
Before treatment, no patient had values for wall thick- 
nesses or chamber dimension outside the adult reference 
range of our clinic. After the 6 months of treatment, no 
significant changes were noted concerning the measured left 
ventricular posterior wall, left atrium, or interventricular 
septum thickness or the LVESD, LVEDD, or fractional short- 
230 
180 
0 r I 1 
0 2 4 6 
Months 
FIG. 2. Changes in maximal power output after GH treatment (closed 
symbols) or placebo (open symbols). No significant differences existed 
between groups at baseline: **, P < 0.01. 
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TABLE 2. Maximal ventilation, anaerobic threshold, maximal 
power output 
Treatment Baseline 6 months P 
Maximal ventilation (Wmin) 
rhGH 53.4 -t 6.3 59.4 + 6.0 10.05 
Placebo 50.5 -c 5.3 53.9 t 5.7 NS 
Anaerobic threshold/kg BW 
(mL/minkg) 
rhGH 16.9 ? 1.8 20.4 -t 1.7 CO.01 
Placebo 16.04 i- 1.0 18.4 2 1.2 0.05 
Maximal power output 
(watts) 
rhGH 192.5 -c 13.5 227.5 + 11.5 ~0.01 
Placebo 187.5 k 16.8 192.5 % 14.9 NS 
Maximal power output BW 
(watts/kg) 
rhGH 2.2 k 0.17 2.4 i- 0.18 ~0.01 
Placebo 2.1 -c 0.19 2.1 i- 0.13 NS 
Maximal power output/lean 
body mass (watts/kg) 
rhGH 3.7 i- 0.3 3.5 5 0.3 NS 
Placebo 3.8 t 0.2 3.8 2 0.1 NS 
Exercise time (min) 
rhGH 6.35 t 0.6 6.77 k 0.5 CO.05 
Placebo 6.05 2 0.7 6.17 k 0.6 NS 
Values are the mean ? SE. No significant differences existed be- 
tween groups at baseline. 
TABLE 3. Echocardiographic results 
Treatment Baseline 6 months P 
IVS (mm) 
rhGH 
Placebo 
LVPW (mm) 
rhGH 
Placebo 
LV-ESD (mm) 
rhGH 
Placebo 
LV-EDD (mm) 
rhGH 
Placebo 
FS (%) 
rhGH 
Placebo 
LVM (g) 
rhGH 
Placebo 
LA (mm) 
rhGH 
Placebo 
LVM/body surface area (g/m’) 
rhGH 
9.3 -c 1.1 9.3 5 1.1 
9.3 k 0.7 9.6 -t 0.6 
8.0 k 0.8 8.3 rfr 0.8 
8.0 i- 0.6 8.6 5 0.5 
31.8 2 1.2 32.3 k 1.1 NS 
31.7 + 2.2 31.1 k 2.1 NS 
48.7 + 1.5 49.2 + 1.5 
48.9 f 2.7 48.9 k 2.1 
35.3 k 0.8 35.2 k 1.0 
35.7 2 1.5 36.7 t 1.7 
148.1 2 24.5 153.9 + 25.2 
158.9 i- 30.3 156.4 k 17.2 
38.0 -t 0.8 37.8 i- 1.1 
38.5 2 0.8 39.5 + 0.9 
73.8 k 9.7 77.2 t- 10.8 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.058 
Placebo 63.1 k 6.7 66.7 k 6.6 NS 
Values are the mean ? SE. No significant differences existed be- 
tween groups at baseline. P < 0.05 was considered significant. LVM/ 
body surface area shows a trend to increase during hGH replacement 
therapy. IVS, inter-ventricular septum; LVPW, left ventricular pos- 
terior wall; LV-ESD, left ventricular end-systolic dimension; LVEDD, 
left ventricular end-diastolic dimension; FS, fractional shortening; 
LVM, left ventricular mass; LA, left atrium. 
ening (FS; Table 3). LVM (&SE) increased slightly, but not 
statistically significantly, from 148.1 ? 24.5 to 153.9 +- 25.2 g. 
When expressed as LVM per body surface area, we found a 
tendency (P = 0.058) to higher values only in the verum 
group after 6 months of treatment (from 73.8 -C 9.7 to 77.2 2 
10.8 g/m*). It should be noted that in only 60% of the patients 
was a reliable echocardiographic result obtained, because of 
technical difficulties due to the high BMI of the patients. The 
maximal systolic (from 188.6 + 9.3 to 194 + 14.2 mm Hg) and 
diastolic (from 105 + 5.5 to 104.7 2 5.4 mm Hg) blood pres- 
sures as well as the maximal heart rate (from 140.9 +- 5.8 to 
144 2 6.9 beats/min) showed no significant change in either 
group after 6 months of hGH treatment. 
Side-effects. Transient side-effects were observed only in the 
verum group in four patients, during the first 6 weeks of 
treatment. All four patients developed edema. Three of these 
four patients also reported muscle pain, and two of them 
fatigue. In two patients, the hGH dose was reduced to 6.25 
pg/kg BW.day, and in all patients, the side-effects dissolved 
within 3-6 weeks. 
Discussion 
Over the 6-month period of hGH replacement, IGF-I levels 
increased in 10 patients with proven hGH deficiency, but 
remained constant in the 10 placebo-treated patients. Our 
findings of an increase of 5 kg in lean body mass, as assessed 
by potassium-40 counting, is in good agreement with pre- 
vious reports (5). This increase in lean body mass reflects, in 
particular, muscle mass. Studies in normal subjects (14) have 
shown that GH increases muscle protein synthesis, as also 
demonstrated by the St. Thomas group (15). Joergensen et al. 
(16) reported that the increase in lean body mass is combined 
with an increase in isometric muscle strength. 
Little is known concerning the effects of hGH replacement 
therapy on static and maximal respiratory function. Initial 
studies (17-19) could not detect an effect of hGH on these 
parameters. 
Furthermore, our data show that GH deficiency in adults 
is associated with a decrease in the pulmonary parameters 
measured by spiroergometry compared to those in a refer- 
ence population (20), and parameters reverted to normal 
during hGH replacement. Especially the data for VO, max 
per kg BW increased from levels below the normal range to 
even slightly above the normal range, and this increase in 
VO, max was associated with improved power output. 
The improvement in VO, max was even more pronounced 
when corrected for total body weight. When related to lean 
body mass, however, no alterations in VO, max could be 
demonstrated in either group. These results underline the 
fact that the increase in lean body mass is an important factor 
for the improvement of VO, max (21), especially as the VO, 
max during maximal exercise occurs almost exclusively in 
the exercising muscles as blood is shunted away from the 
splanchnic bed (22). 
According to the data of Joergensen et al. (16), the increase 
in lean body mass especially reflects an increase in muscle 
tissue and, therefore, might result in an increase in respira- 
tory muscle strength. The fact that we could find an increase 
in the maximal ventilation volume supports the assumption 
that the increase in respiratory muscle strength during hGH 
treatment might partially influence the maximal oxygen up- 
take. The changes during hGH treatment in muscle volume 
per se might play an important role in the changes in VO, 
556 NASS ET AL. JCE & M . 1995 
Vol80. No 2 
max. In this context, it is interesting to note that Fleg and 
Laketta (23) showed that the age-related muscle loss is as- 
sociated with a progressive decline in VO, max. 
As our patients received adequate and constant hormone 
replacement therapy with T,, glucocorticoids, and gonadal 
steroids for 12 months before and during the trial, we con- 
clude that the changes observed are not influenced by the 
standard replacement therapy, especially the glucocorticoid 
or testosterone therapy in male patients, but are caused by 
hGH. Our patients were advised not to change their diets or 
daily activities, but they were not restricted in this respect. 
The analysis of the daily activity questionnaires showed no 
significant increase in daily activity during the 6 months of 
treatment in either group. During the 6-month treatment 
period, the patients reported no change in daily diet. 
It is our opinion that both direct metabolic effects of hGH 
as well as possible indirect psychological effects (24), leading 
to increased physical activity, may have contributed to the 
increase in power output. The anaerobic threshold showed 
a significant increase in both groups, but with a higher in- 
crement in the hGH-treated group. The remarkable increase 
in the anaerobic threshold, especially in the verum group, 
might be due to the improved oxygen consumption under 
hGH replacement. 
The increase in the 0, pulse in the group treated with hGH 
underlines the positive effect of hGH on the cardio-pulmo- 
nary exercise performance and might contribute to the im- 
provement in exercise capacity during hGH treatment. The 
fact that the maximal 0, pulse increased significantly during 
hGH treatment could be explained by an increased cardiac 
output under the assumption that arterio-venous O2 content 
is not altered by hGH treatment, an idea that requires con- 
firmation. This is an indirect conclusion, as we did not mea- 
sure the arterio-venous O2 content difference. Our data show 
a significant increase in oxygen uptake per heartbeat under 
hGH treatment, and this effect might be due to increased 
peripheral oxygen consumption or might be explained by an 
increased cardiac output and, therefore, reflects an increased 
stroke volume. 
The assumption that GH increases cardiac output in GH- 
deficient patients is supported by the findings of Merola et 
al. (25), who described a decreased ejection fraction in GH- 
deficient adults. Furthermore, Cuneo et a/.(26) could show in 
one case the increase in cardiac output in a patient with 
dilated cardiomyopathy, and Thuesen et al. (27) showed an 
increase in cardiac output in normal subjects during hGH 
treatment. We, therefore, examined cardiac structure by 
echocardiography. 
In contrast to previous results, we could not detect any 
significant changes measured by echocardiography concern- 
ing either the cardiac function or the cardiac structure of our 
patients. The only changes were a slight, but not significant, 
increase in the LVM, as expressed per body surface area. 
Cuneo and co-workers (8) described an increase in left ven- 
tricular myocardial mass after 6 months of hGH treatment of 
GH-deficient adults as well as an increase in stroke volume. 
The other parameters (LVESD, FS, and wall thickness) 
showed no significant differences after hGH treatment. The 
discrepancy between our data and those of Cuneo ef al. (8) 
might be explained by the lower hGH dosage used in our 
study. This suggestion is supported by the data from the 
Aarhus group (16), who could not detect any changes in the 
left ventricular wall mass using a hGH dosage comparable 
to that we used. 
According to Cuneo et al. (28), the increase in stroke vol- 
ume after hGH treatment may reflect increased preload (Star- 
ling effect) due to the sodium-retaining effect of hGH, which 
results in an increased circulating blood volume. It appears 
that in our study this effect played a minor role, as LVEDD 
determined by echocardiography did not increase during 
hGH treatment. 
Furthermore, it is important to note that left ventricular 
dimensions and wall thicknesses were within normal limits 
before and after treatment in our study group. According to 
these data, we conclude that hGH in physiological replace- 
ment dosage does not change cardiac structure and seems 
not to affect myocardial structure, as observed in acromegaly 
(29). Concerning cardiac function, on the other hand, ac- 
cording to our 0, pulse data, hGH might increase stroke 
volume, a fact that has been reported previously by others 
(26). We cannot comment on this observation by using echo- 
cardiographic measurements, because we do not consider 
the FS determined echocardiographically to be a reliable 
parameter for stroke volume. 
The observation that hGH does not change the cardiac 
structure, but does affect cardiac stroke volume, might be 
explained by the fact that hGH therapy also alters the muscle 
fiber metabolism (30). Furthermore, the increase in VO, max 
and in the anaerobic threshold during hGH therapy might be 
influenced by changes in energy metabolism. 
Press (31) showed that GH enhances carbohydrate metab- 
olism and muscle and hepatic glycogen stores. Lipid metab- 
olism seems to play no role in the increase in exercise per- 
formance (32, 33). 
To our knowledge, no data exist concerning changes in the 
oxygen transport capacity of erythrocytes during hGH ther- 
apy. We did not detect changes in the whole erythrocyte 
mass in either group (data not shown), and this parameter 
seems to play a minor role in the observed improvement in 
V02 max. 
The highly significant increases in the exercise time and 
power output suggest that the beneficial effects of hGH treat- 
ment on pulmonary parameters (VO, max and anaerobic 
threshold) improve physical work capacity. It is, therefore, 
conceivable that tasks of every day life can be performed by 
the patients with more ease. 
In summary, according to our data, adults with GH de- 
ficiency acquired in adulthood show decreased VOZ max 
compared to that in a reference population, which can be 
normalized by hGH replacement therapy. Furthermore, dur- 
ing hGH treatment, we found a significant increase in lean 
body mass. After 6 months of treatment with hGH, exercise 
performance, as well as VO, max, anaerobic threshold, and 
O2 pulse improved significantly. Cardiac structure showed 
no significant changes during our low dosage hGH replace- 
ment regimen, whereas functional improvements, probably 
due to improved muscle metabolism, might contribute to the 
improved exercise performance. 
As the increase in lean body mass in our study parallels the 
improvement in VO, max and exercise performance, we 
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conclude that the increase in muscle mass is a major reason 
for these observations. Investigations over longer study pe- 
riods are mandatory to arrive at further conclusions con- 
cerning the effects of hGH in adults on body composition and 
exercise performance, especially with respect to possible ad- 
verse long term effects, which were not observed in this 
study. 
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